Blockchain Registration Transaction Record

Regentis Biomaterials Advances GelrinC for Knee Cartilage Repair

Regentis Biomaterials advances GelrinC, a cell-free hydrogel implant for knee cartilage repair, addressing a major unmet need in orthopedics with a single-procedure solution.

This news matters because knee cartilage damage affects hundreds of thousands of patients annually, yet no off-the-shelf regenerative solution is approved in the U.S. GelrinC could transform treatment by offering a simple, single-procedure implant that avoids the drawbacks of existing therapies. If successful, patients may experience faster recovery and long-term restoration of function, reducing the need for multiple surgeries and improving quality of life. For investors, Regentis's progress in FDA trials and manufacturing innovations signals a potential breakthrough in a multi-billion dollar market.